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ABSTRACT
Many medical conditions are marked by a sequence of events or statuses that are associated
with continuous changes in some biomarkers. However, few works have evaluated the overall
accuracy of a biomarker in separating various competing events. Existing methods usually
focus on a single cause and compare it with the event-free controls at each time. In our study,
we extend the concept of ROC surface and the associated volume under the ROC surface
(VUS) from multi-category outcomes to ordinal competing risks outcomes. We propose two
methods to estimate the VUS. One views VUS as a numerical metric of correct classifica-
tion probabilities representing the distributions of the diagnostic marker given the subjects
who have experienced different cause-specific events. The other measures the concordance
between the marker and the sequential competing outcomes. Since data are often subject to
lost of follow up, inverse probability of censoring weight is introduced to handle the missing
disease status due to independent censoring. Asymptotic results are derived using counting
process techniques and U-statistics theory. Practical performances of the proposed estima-
tors in finite samples are evaluated through simulation studies and the procedure of the
methods are illustrated in two real data examples.
Public Health Significance: ROC curve has long been treated as a gold standard in
evaluating the accuracy of continuous predictors in separating binary outcomes in various
fields including biomedical, financial, and geographical areas. Our proposed methods extend
its utilization in multi-category events outcomes to competing risks censoring. Our methods
v
aim to assess a global accuracy of a biomarker’s predictive power to each simultaneously,
especially, to which stages of disease progression that patients would land by a specific time
in followup. Our work provides much-needed global assessment for the predictive power of
a biomarker for disease progression.
Keywords: Concordance probability; Correct classification probability; Discriminative ca-
pability; Disease progression; Inverse probability of censoring weighting; U-statistics.
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1.0 INTRODUCTION
In biomedical studies, it is often of interest to measure a biomarker’s predictive power for
future events. Accurate diagnostic analysis can help clinicians screen high-risk subjects,
which in turn will lead to timely and efficient therapeutic interventions and reduced mortality
and morbidity. A time-dependent ROC curve was proposed by Heagerty et al. (2000) to
extend diagnostic accuracy analysis from a binary outcome to a typical survival outcome,
summarizing sensitivity and specificity at a specific time t0. Assuming a lower biomarker
value is associated with a worse outcome, the area under the ROC curve (AUC) can be
interpreted as a concordant probability that for a randomly selected pair of a case (i.e.,
developing the event of interest by t0) and a control (no event by t0), the biomarker value
from the case is lower than that from the control. A lot of works have shown that the AUC
is an expression of Mann-Whitney U statistics (Faraggi and Reiser, 2002). Heagerty and
Zheng (2005) presented their work in constructing predictive accuracy measure for survival
outcomes by fitting Cox regression models.
Competing risk censoring commonly arises in studies where subjects are at risk for mul-
tiple failures, and one failure precludes the observation of the others or alters the proba-
bility of occurrence of the others (Gooley et al., 1999). For instance, in the Monongahela-
Youghiogheny Healthy Aging Team (MYHAT) study, if we took the onset of mild/moderate
cognitive impairment (MCI) or dementia as a primary interest, when a patient died without
cognitive decline, the onset of MCI/dementia would be competing-risk censored by death.
Note that the mechanism of “redistribution to the right” (Efron, 1967), is limited to the
assumption of independent censoring in Kaplan-Meier methods and Cox models, and thus
is not valid in competing risks censoring. With independent censoring, the likelihood con-
tribution from censoring data which amounts to a constant in estimating parameters of
1
interest, should not affect inference. However, the share of risks from competing events 
will not be distributed to the other subjects at the riskset due to interactions between the 
competing events. A fundamental proof from Tsiatis (1975) showed that the dependence 
among competing events was not non-parametrically identifiable given only observed data, 
so the observed data alone is not sufficient to identify the marginal distributions of the la-
tent variables without imposing their dependence structure. More specifically, even under a 
parametric model with its maximum likelihood estimator producing consistent estimators, 
it is not possible to assess whether the models are correctly specified. A popular quantity 
for measuring the cumulative probability of the event of interest by a specific time is the 
cumulative incidence function (CIF) (Prentice et al., 1978; Kalbfleisch and Prentice, 2011), 
since the survival function for a specific event may not be well defined. It has been widely 
employed due to its intuitive probability interpretation and non-parametric identifiability.
Expanding the ROC concept to competing risks consoring, Saha and Heagerty (2010) 
proposed to estimate the sensitivity with cumulative cases accruing to a fixed time, and to 
estimate the specificity among “healthy” control subjects (i.e., those without developing any 
event yet). Following similar definitions of sensitivity and specificity, Zheng et al. (2012) 
evaluated prognostic accuracy with multiple covariates using both Cox (1959) and more 
flexible Scheike et al. (2008) models. Blanche et al. (2013a) and Wolbers et al. (2014) used 
nonparametric inverse probability of censoring weighting (IPCW) to derive the estimators of 
AUCs and their asymptotic properties. Some of these analyses compare cases from each cause 
to the event-free control at each time. One limitation of the above methods is that there is no 
overall predictive accuracy assessment across all of events simultaneously, since different cases 
are considered for each specific cause in separate ROC analyses. In contrast, Shi et al.(2014) 
evaluated the improved accuracy of new markers for competing outcomes by defining 
“controls” that combine both event-free subjects and those who have developed competing 
events. Though the definition of the “control” group is in line with the augmented “at-risk” 
set in Fine and Gray (1999), it may not be ideal if subjects with competing events are very 
different from those without any event. To the best of our knowledge, the existing methods are 
not adequate in evaluating a biomarker’s discriminatory power on competing outcomes, 
since they either do not provide a global assessment of accuracy across all competing events,
or have to force unnatural grouping of competing events with healthy controls.
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Medical conditions often manifest a natural ordinal disease status. For example, in the 
MYHAT study, disease progresses through several sequential stages: normal cognitive 
function, mild to moderate cognitive impairment, severe dementia and death. Also, patients 
with cirrhosis follow a series of continuous progression marked by various stages of disease 
severity. Following onset of viral liver hepatitis, patients can be observed with declining liver 
functions to fibrosis, which is marked as normal liver cells replaced by functionless scar tissue 
in mild level (less than 25% scar tissue), and then deteriorating to cirrhosis which is 
characterized with severe liver cell damage with 50% to 75% scar tissue, and finally they die 
with complications due to collapse of liver function. An important aim in clinical practices is 
to characterize a sequence of progressive status based on continuous changes in a prognostic 
biomarker. With multi-level progressive status, Obuchowski (2005) pointed out that simply 
dichotomizing an ordinal outcome led to upward bias in diagnostic testing using ROC curve. 
Mossman (1999) introduced the concept of multi-dimensional ROC surface and the Volume 
Under the ROC Surface (VUS) by evaluating discriminatory accuracy of two diagnostic tests 
for three disease categories. The variance of Mossman (1999)’s VUS estimator was derived by 
Dreiseitl et al. (2000) based on the theory of U-statistics. Li and Fine (2008) applied the 
concept of VUS to unordered multilevel categorical outcomes and further expanded multi-way 
ROC analysis and the summary statistics of Hypervolume Under the ROC Manifold (HUM). 
Li and Zhou (2009) studied the estimated VUS using nonparametric and semiparametric 
methods and developed asymptotic properties of the estimators. Wu and Chiang (2013) 
showed through a rigorous proof that HUM is directly related to an explicit U-estimator.
However, there is no well-developed method to assess the global accuracy in a biomarker’s 
prediction of which stage of disease progression a subject would land by a specific time. Thus, 
we propose to utilize the concept of the ROC surface (or ROC manifold) and the VUS (or 
HUM) to demonstrate the prognostic accuracy of a biomarker to competing risks outcomes. 
Here, we focus on the competing events with a natural order, as we have observed in the 
MYHAT study. The rest of the dissertation is organized as follows. In §2, we introduce the 
concept of the ROC surface and the associated VUS from two perspectives. One is to employ
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the building blocks of an ROC surface, namely correct classification probabilities (CCPs),
to derive VUS. The second is to measure a concordance probability between the biomarker
and the competing outcomes. Subsequently, two methods are proposed to estimate the VUS
from these two perspectives in §3 and §4, and their asymptotic properties are investigated.
A real data analysis phenomenon of adaption tied scores in biomarker using our proposed
methods is discussed in §5. In §6, we study the finite sample performances of our proposed
estimators through simulations, and illustrate our methods through the analyses of two real
data examples in §7. In the end, we summarize our work and discuss some future research
ideas in §8.
4
2.0 ROC SURFACE FOR ORDINAL COMPETING RISKS OUTCOMES
2.1 NOTATION
Without loss of generality, we now consider the diagnostic accuracy of one single biomarker
in predicting two ordered competing risks outcomes, referred as a cause-1 event and a cause-
2 event. The cause-1 event is assumed to be a worse medical condition, as compared to
healthy controls. Let Y denote a diagnostic biomarker where lower values correspond to
worse medical conditions. In practice, a biomarker may have tied values. Discussions on
how to handle ties are given in §5 and the corresponding simulation results are given in
§6. Let T be the time to any ordinal competing events, and ϵ = 1, 2 be the corresponding
cause of failure. At a fixed time t0, if both competing events have occurred, the more severe
progression time is recorded as T and ϵ is set to be 1. We then define disease status D(t0)
as:

D (t0) = 1, if T ≤ t0, ϵ = 1,
D (t0) = 2, if T ≤ t0, ϵ = 2,
D (t0) = 0, if T > t0.
In practice, there may be administrative censoring C, in addition to competing risks censor-
ing. Thus, we observe X = min (T,C) and the combined cause indicator η = I (T ≤ C) ϵ,
where I (·) is an indicator function. The observed data consist of i.i.d replicates {(Yi, Xi, ηi) , i = 1, . . . , n}.
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2.2 ROC SURFACE
Analogous to sensitivity and specificity that describe the level of accuracy by specifying
a series of cutpoints along with a continuous classifier for a binary outcome, we need two
cutpoints (c1, c2) ∈ R2 from Y with c1 ≤ c2 for the two competing events, where we assign
a subject to Class 1 if their biomarker Y ≤ c1, to Class 2 if c1 < Y ≤ c2, and to Class
3, otherwise. Correct classification probabilities (CCPs) are then defined for the subjects
experiencing a cause-1 event, a cause-2 event, or none of the events at a given time t0 as
follows:
CCP1 = P (Yi ≤ c1|Ti ≤ t0, ϵi = 1) = FY |1(c1),
CCP2 = P (c1 < Yi ≤ c2|Ti ≤ t0, ϵi = 2) = FY |2(c2)− FY |2(c1),
CCP3 = P (Yi > c2|Ti > t0) = 1− FY |3(c2),
where FY |d(y) = P (Y ≤ y|D(t0) = d), d = 1, 2, 3, is the conditional cumulative density
function (CDF) of the biomarker Y , given that the subject is in a particular disease status.
Also, similar to the ROC curve characterizing the full spectrum of sensitivity and specificity
in a two-dimensional space, the plot of (CCP1, CCP2, CCP3) in a three-dimensional space at
all possible values of (c1, c2) generates a three-dimensional ROC surface for three-category
time-dependent outcomes. Following Li and Zhou (2009), the ROC surface is defined by
expressing CCP2 as a function of CCP1 and CCP3:
Q(u, v) =
{
FY |2{F−1Y |3(1− u)} − FY |2{F
−1
Y |1(v)} if F
−1





The ROC surface can also be formulated by using CCP1 or CCP3 as a function of the other








To having a feel if the ROC surface and its associated VUS, we present the estimated
ROC surfaces in Figures 2.1 and 2.2 under different different predictive powers of a biomarker
to the ordinal competing outcomes, where cases of death (the cause-1 event) and dementia
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(the cause-2 event) are compared to the healthy controls simultaneously. In Figures 2.1, left
ROC surface represents strong predictive power of a biomarker to the ordinal competing
events which VUS is equal to 0.79, and right ROC surface represents moderate predictive
power between a biomarker and the competing events for VUS = 0.49. Also in Figure 2.2,
left ROC surface represents weak predictive for VUS = 0.35 and right one represents no
predictive power for VUS = 0.167. The details of estimating the ROC surface and VUS are
discussed in §3. Figures seem to suggest that the VUS is a sensitive global mesasure of the
strength of the association between the marker and the competing risks outcomes.
2.3 VUS CORRESPONDING TO A CONCORDANCE INDEX
According to previous works of Mossman (1999), Dreiseitl et al. (2000) and Wu and Chiang
(2013), the VUS also corresponds to a concordance measure between the biomarker values
and the sequential competing risks outcomes. Suppose we randomly select three subjects 1,
2, 3 such that T1 ≤ t0, ϵ1 = 1, T2 ≤ t0, ϵ2 = 2 and T3 > t0. Their biomarkers are denoted as
Y1, Y2 and Y3, respectively. It can be shown that
V US = P (Y1 < Y2 < Y3|T1 ≤ t0, ϵ1 = 1, T2 ≤ t0, ϵ2 = 2, T3 > t0). (2.3.1)











































Figure 2.1: ROC surface for strong predictive power and moderate predictive power of a biomarker









































Figure 2.2: ROC surface for weak predictive power and no predictive power of a biomarker to
ordinal competing events
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3.0 ESTIMATION OF THE ROC SURFACE AND VUS
3.1 NONPARAMETRIC ESTIMATION OF THE THREE-DIMENSIONAL
ROC SURFACE AND VUS
Nonparametric methods are used to estimate FY |d(y), d = 1, 2, 3 for any pair of (y, t0). In
terms of estimating the conditional distribution of Y given the subjects experiencing either
the cause-1 event or the cause-2 event by t0, we have
FY |k(y) = P (Y ≤ y|D(t0) = k)
=
P (Yi ≤ y, Ti ≤ t0, ϵi = k)
P (Ti ≤ t0, ϵi = k)
,
where k = 1, 2. The numerator is a joint bivariate CIF and the denominator is a univariate
CIF. We adopt the bivariate CIF estimator in Cheng et al. (2007), F̂Y,T (t0), to estimate the
joint bivariate probability, which includes the biomarker Y as a special case being completely
observed without censoring. The univariate CIF is estimated by the standard nonparametric
estimator F̂T (t0). Also, we formulate the conditional distribution of Y for those subjects who
have not developed any events by t0 in terms of a bivariate survival function and a univariate
survival function:
FY |3(y) = P (Y ≤ y|D(t0) = 3)
=
P (Yi ≤ y, Ti > t0)
P (Ti > t0)
=
P (Ti > t0)− P (Yi > y, Ti > t0)
P (Ti > t0)
=




The bivariate survival estimator ŜY,T (t0) (Dabrowska, 1988) is used to estimate the bivariate
survival function SY,T (t0) and the Kaplan-Meier estimator ŜT (t0) is used for the univariate
survival function ST (t0). Plugging the estimators into the definition of the three-dimensional
ROC surface, we have
Q̂(u, v) = F̂Y |2{F̂−1Y |3(1− u)} − F̂Y |2{F̂
−1
Y |1(v)}, (3.1.1)
if F̂−1Y |1(v) ≤ F̂
−1
Y |3(1− u).







The resulting estimated ROC surface are increasing step functions jumping at event
times. We approximate the V̂ US(t0) by summation of the volumes of rectangular prisms
for their lengths, widths and heights corresponding to the CCP1, CCP2, CCP3 given the
varying threshold pairs of (c1, c2).
3.2 ASYMPTOTIC PROPERTIES AND INFERENCE OF V̂ US(T0)
The estimation procedure of V̂ US(t0) includes the estimation of the conditional CDF of
biomarker Y given the particular disease status and the surface under the ROC curve. Bayes
principle allows formulating the conditional distributions FY |1(y) as
FY |1(y) = P (Y ≤ y|D(t0) = 1)
=
P (Ti ≤ t0, ϵi = 1|Yi ≤ y)P (Yi ≤ y)
P (Ti ≤ t0, ϵi = 1)
,
where P (Ti ≤ t0, ϵi = 1|Yi ≤ y) is the conditional CIF of the cause-1 event given the subset
Yi ≤ y. The same idea is also applied to FY |2(y)and FY |3(y) and we have
FY |2(y) =
P (Ti ≤ t0, ϵi = 2|Yi ≤ y)P (Yi ≤ y)




P (Ti > t0|Yi ≤ y)P (Yi ≤ y)
P (Ti > t0)
.
Counting process and martingale theory (Kalbfleisch and Prentice, 2011) can be utilized
in deriving the influence functions for Kaplan-Meier estimators of survival functions and
nonparametric estimators of CIF. IFY/d(y), the influence functions of FY |d(y) for d = 1, 2, 3,
are developed through Taylor’s expansion incorporating the elements of the marginal and the
conditional CIF (or survival function), as well as the empirical distribution of Y. Hadamard-
differentiability and functional delta method are used in constructing the influence function
of the surface under ROC curve IQ(u,v) with respect to its presentation containing quantile
function and compound function. The asymptotic normality of V̂ US(t0) is stated in the
following theorem.
Theorem 3.1: Let ν1 > inf {u : F (u) > 0} and ν2 < sup {u : SX(u) > 0} and t0 in [ν1, ν2].
Subject to independent censoring, the estimated VUS for the ordered competing risks out-
comes associated with the prognostic biomarker Y through their correct classification prob-
abilities at t0 are uniformly consistent and asymptotically normally distributed and we can
write
√










is the influence function of V̂ US(t0).
The work on the proof of Theorem 3.1 is presented below with great details. The esti-











Given V̂ US(t0) is asymptotic normal, we construct a Wald-type (1− α) confidence interval













• Proof of Theorem 3.1
In estimating the variance of V̂ US, we develop its influence function based on the esti-
mating procedures of the conditional CDF of the biomarker Y given the subjects falling
into each of the three disease statuses FY |d(y) and ROC surface Q(u, v). The Bayes
theorem formulates FY |d(y) for d = 1, 2, 3 as a ratio of the conditional CIF of the cause-1
event (or the conditional CIF of the cause-2 event, or the conditional survival function)
with the CDF of the biomarker Y , over the marginal CIF the cause-1 event (or the
marginal CIF of the cause-2 event, or the marginal survival function). The survival
function S(t0) = P (T > t0) and the cause-specific CIF is defined with association of the
survival function and its cause-specific hazard:












P (t0 ≤ T ≤ t0 + h, ϵ = k | T > t0)
h
.
Also, let Λ = Λ1 + Λ2. In real dataset, we observe the triplet (Xi, ηi, Yi). In counting
process formulation, we specify the right-continuous process of the cause-specific events
as:





as well as the combined events
Ni(s) = N1i(s) +N2i(s),
N.(s) = N1.(s) +N2.(s).
where I(·) is an indicator function. Also, the left-continuous process of the subjects at
riskset is











And Mi(s) = N.(s)−
∫ s
0
Ri(u) dΛ is another martingale process.




















A body of literature has been devoted to explore their influence functions (Pepe, 1991;
Lin, 1997; Zhang and Fine, 2008) for their asymptotic properties. Under regular condi-
tions, the influence functions of the estimators for survival functions and the cumulative
incidence functions in the competing risks are
√















































for k = 1, 2. The kaplan-Meier estimators and the nonparametric estimators of CIFs are















. (s) have the same defini-
tions of N1i(s), N2i(s), Ni(s), N1.(s), N2.(s), N.(s), Ri(s), and R.(s) within the subset
Yi ≤ y when y follows the distribution of Y . Analogous to the aforementioned estimators



























with y index the estimators or parameters associated with the subset Yi ≤ y. The mar-
















The influence functions of conditional survival function and condition CIF in the subset
of Yi ≤ y are modified
√















ISyi (t0) + op(1);
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√































and k = 1, 2.
The influence function of the empirical distribution of CDF F (y) is
√











IFi(y) is estimated by plugging in the estimated empirical cumulative density distribution
F̂ (y) for F (y).






FG(Ê− E) + EG(F̂− F)− EF(Ĝ−G)
G2
+ op(1). (3.2.1)
For illustration, we show details about derivation of the influence function of the condi-
tional distribution FY/3(y) as
E = P (Ti > t0|Yi ≤ y) = Sy(t0),
F = P (Yi ≤ y) = F (y),
G = P (Ti > t0) = S(t0),


















By filling in each elements back to the Taylor expansion equation (3.2.1), we yield
√















IF(Y |3)i(y) + op(1), (3.2.2)
and we estimate the influence function of F̂Y |3(y) by plugging in F̂ (y), Ŝ(t0), Ŝ
y(t0) for
F (y), S(t0), S
y(t0).
With the same approach, the influence functions of F̂Y |k(y) for k = 1, 2 are written as:
√


















IF(Y |k)i(y) + op(1), (3.2.3)
Similarly, we estimate the influence function of F̂Y |1(y) and F̂Y |2(y) by plugging in
F̂ (y), F̂1(t0), F̂
y
1 (t0), F̂2(t0), F̂
y
2 (t0) for F (y), F1(t0), F
y
1 (t0), F2(t0), F
y
2 (t0).
The influence function in estimating the surface of ROC curve, Q(u, v) = FY |2(F
−1
Y |3(1−
u)) − FY |2(F−1Y |1(v)), if F
−1
Y |1(v) ≤ F
−1
Y |3(1 − u), is achieved by evaluating the asymptotic





for l = 1, 3. The quantile function F−1Y |l(τ) = inf
(
y : FY/l(y) ≥ τ, τ ∈ (0, 1)
)
in the competing risks framework, which is the smallest value of y at which the prob-
ability of event l exceeding τ in the presence of other competing events. Since F−1 is










−IF(Y |l)i(y) ◦ F
−1
Y |l(τ)









(τ) + op(1), (3.2.4)
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where fY |l(y) is the first derivative of FY |l(y) and ◦ is a mathematical operator of function
composition. IF(Y |l)i have been specified in equations (3.2.2) and (3.2.3) respectively.
F−1Y |l(τ) can be estimated with the inverse function of F̂Y |l(τ), where τ can be replaced
by v or 1− u corresponding to l = 1 or 3.
In term of the inference of F̂Y |2(F̂
−1
Y |l(τ)), we took the idea of asymptotic features of the
compound function from quantile association for bivariate survival data (Li et al., 2017).
We assume the following regularity conditions:
1. fY |2(y) is the first derivative of FY |2(y) and
∣∣fY |2(y)∣∣ is bounded uniformly in (τL, τU),
and τL, τU are within (0, 1) representing the lower and upper bounds of quantile range
of interest.
2. F−1Y |l(τ) is Lipschitz continuous while τ ∈ (τL, τU).
We need to express F̂Y |2(F̂
−1
Y |l(τ)) − FY |2(F
−1
Y |l(τ)) with respect to two presentations to
examine its uniform consistency and weak convergence respectively. Firstly in examining
uniform consistency of F̂Y |2(F̂
−1
Y |l(τ)), we write the formula as:
sup
τ∈(τL,τU )
∣∣∣F̂Y |2(F̂−1Y |l(τ))− FY |2(F−1Y |l(τ))∣∣∣ ≤ sup
τ∈(τL,τU )
∣∣∣F̂Y |2(F̂−1Y |l(τ))− FY |2(F̂−1Y |l(τ))∣∣∣
+ sup
τ∈(τL,τU )
∣∣∣FY |2(F̂−1Y |l(τ))− FY |2(F−1Y |l(τ))∣∣∣
We have shown that F̂Y |2(y) is uniformly consistent to FY |2(y) given equation (3.2.3)
and F̂−1Y/l(τ) is uniformly consistent to F
−1
Y/l(τ) given equation (3.2.4). Assembling both
evidences, given |fY |2(y)| as bounded, F̂Y |2(F̂−1Y |l(τ))−FY |2(F
−1
Y |l(τ)) → 0 uniformly while
τ ∈ (τL, τU) as n → ∞.










































weakly to a Gaussian process with mean 0 given equation (3.2.3). The influence function
of F̂Y |2(F
−1
Y |l(τ)) is obtained by modifying IF(Y |2)i(y) with y replaced by F̂
−1
Y/l(τ), which we
denote as IF(Y |2)iF−1(Y |l)(τ).
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Furthermore, together with the quantile function F̂−1Y |l(τ) uniformly converging to F
−1
Y |l(τ),


































Y |l(τ)) is the first derivative of the conditional CDF FY |2(F
−1
Y |l(τ)) evalu-
ated at F−1Y |l(τ). I
−1
F(Y/l)i
(τ) can be derived from equation (3.2.4). Combining the two



























IF(Y |2)iF−1(Y |l)i(τ) + op(1).
Summarizing the results above, the inference of Q̂(1− u, v) is produced with the simple





































































Therefore, we have the asymptotic weak convergence of V̂ US(t0) over t0 ∈ [ν1, ν2] as
defined in Theorem 3.1.
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4.0 CONCORDANCE DEFINITION BASED ESTIMATION OF VUS
4.1 IPCW-ADJUSTED ESTIMATION OF VUS ACCORDING TO THE
CONCORDANCE DEFINITION
Without independent censoring, the disease status by a fixed time D(t0) would be observed
for each subject in the sample. A U-type VUS estimator can be constructed according to
randomly selecting three subjects, each from one type of disease status, to reflect concor-
dance relationship between the biomarker and the outcomes. However, in the presence of
independent censoring, there are four possible scenarios for the i-th subject:
I{Xi ≤ t0, ηi = 1} = I{Ti ≤ t0, ϵi = 1, Ci ≥ Ti}
I{Xi ≤ t0, ηi = 2} = I{Ti ≤ t0, ϵi = 2, Ci ≥ Ti}
I{Xi > t0} = I{Ti > t0, Ci > t0}
I{Xi ≤ t0, ηi = 0} = I{Ci ≤ t0, Ti > Ci}.
The disease status D(t0) is determinable for the first 3 scenarios, but not for the fourth
one. To adjust to missing disease statuses due to independent censoring before t0, we adopt
inverse probability censoring weighting (IPCW). IPCW is used to inversely weight the ob-
served subjects of the cause-1 event and the cause-2 event at the selected t0 according to
their probabilities of being observed at the times of event occurrence, and the weights were
estimated based on the censored data. For more information of general theory of IPCW,
we can refer to Van der Laan and Robins (2003). Let G(t) = P (C > t) be the survival
function of censoring, and Ĝ(t) be the Kaplan-Meier estimator of G(t). Following that the
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Kaplan-Meier estimator is a self-consistent estimator with right-censored data redistribu-
tion (Efron (1967); Dinse (1985)), I{Xi ≤ t0, ηi = k}/Ĝ(Xi) is an unbiased estimator of
P (Ti ≤ t0, ϵi = k) for k = 1, 2 and I{Xi > t0}/Ĝ(t0) is an unbiased estimator of P (Ti > t0).



















As a consequence, the VUS estimator is the ratio of the estimated probability of observing
a triplet of subjects each from one of the three disease statuses, with their associated ordered
biomarker, over the estimated probability of observing the triplet each from one of the three
disease statuses.
4.2 CONSISTENCY AND WEAK CONVERGENCE OF Ṽ US(T0)
IPCW is used to account for missing data from independent right-censoring, which weights
the observed subjects by their inverse probability of being observed, and the weight is es-
timated from the censored subjects. IPCW intends to recreate a population which would
have been seen without censored subjects. In the scope of this study, we focus on biomarker-
independent censoring. However, in the presence of biomarker-dependent censoring, without
any modification, IPCW-adjusted estimators might cause some bias due to the degree of as-
sociation between the censoring mechanism and the biomarker. Blanche et al. (2013b) stated
that a little modification of inverse probability of censoring weighting can do a similar job to
the nearest neighbor estimator which was proposed by Heagerty et al. (2000) for biomarker-
dependent censoring. IPCW-adjusted weighting is to weight the observed subjects with the
marginal probability of be censored without accounting for the biomarker’s association to
the censoring, as compared to the modified (conditional) IPCW-adjusted weighting which
is to weight the observed subjects at the time of being observed by conditional probability
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of being censored given the biomarker. In this research, modified IPCW-adjusted weight-
ing is not in our research scope, but it is straightforward to incorporate modified-IPCW
distribution to accommodate a biomarker-dependent censoring given our proposed method.
For now, let Ĝ(t) be the Kaplan-Meier estimator of survival function of censoring G(t) =
P (C > t). As n → ∞, 1
n
∑n
i=1 I(Xi ≤ t0, η = 1)/Ĝ(Xi) converge to
E
{













I(Ti ≤ t0, ϵi = 1)
[
E{I(Ti ≤ Ci)|Xi, ηi}
G(Xi)
]}













converge to P (Tj ≤ t0, ϵj = 2) and P (Tk > t0) respectively.
Base on the proof that the IPCW-adjusted probability of observing those with the cause-
1 event (or the cause-2 event or none of the events) by a fixed time t0 is a consistent to the
probability of subjects experiencing the cause-1 event (or the cause-2 event or none of the
events) by t0, heuristically, with Slutsky’s theorem, we have
E(Ṽ US(t0)) = E
E










I(Ti ≤ t0, ϵi = 1, Tj ≤ t0, ϵj = 2, Tk > t0, Yi < Yj < Yk)
I(Ti ≤ t0, ϵi = 1, Tj ≤ t0, ϵj = 2, Tk > t0)
)
= P (Y1 < Y2 < Y3|Ti ≤ t0, ϵi = 1, Tj ≤ t0, ϵj = 2, Tk > t0).
Given the observed datasetQ = (Xi, Xj, Xk, ηi, ηj, Yi, Yj, Yk), the IPCW-adjusted Ṽ US(t0)
leads to a consistent estimator of V US.
Weak convergence of Ṽ US(t0) using counting process techniques and the theory of U-
statistics results in an explicit formula for the variance estimation, where we adapted the
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proof from Hung and Chiang (2010) for survival data without competing risks events. For a
fixed t0, the asymptotic result of the Kaplan-Meier estimator has its martingale expression










And it can be rewritten as the ratio of
Ĝ(t0)
G(t0)






















P (t0 ≤ C ≤ t0 + h | C > t0)
h
,
and ΛC(·) is estimated by plugging in Nelson-Aalen estimators. Similarly, Ŝ(t0) is an empir-
ical Kaplan-Meier estimator for the survival function S(t0) = P (X > t0).
Theorem 4.1: Given that the censoring variable C is independent of T and t0 is defined
in Theorem 3.1, according to the definition (2.3.1) of VUS, we have
√


















• Proof of Theorem 4.1
We define
Ãijk =
I(Xi ≤ t0, ηi = 1, Xj ≤ t0, ηj = 2, Xk > t0, Yi > Yj > Yk)
G(Xi)G(Xj)G(t0)
where the estimated Âijk is derived by plugging in Kaplan-Meier estimators of Ĝ(·) to
G(·). Let A = E(Ãijk).
Let Cijk = I(Xi ≤ t0, ηi = 1, Xj ≤ t0, ηj = 2, Xk > t0, Yi > Yj > Yk). Using the Taylor

















By invoking the martingale expression from equation (4.2.1),as well as estimation theory


































is a combination expression of m-element subset from the set of 1, · · · , n.
Similarly, we define
B̃ijk =









































(Â− A)− AB (B̂− B)
B
+ op(1).
Assembling the aforementioned results, we derive
sup
t0






i ̸=j ̸=k ̸=p ̸=q ̸=r
Ψijkpqr(t0)

















































U statistics theory (Lee, 1990) is a powerful tool in studying large sample properties.
Belonging to a non-parametric family, U statistics usually are uniformly minimum vari-
ance unbiased estimators (UMVUE) for the parameter θ. For a distribution family F






h(Xi1, . . . , Xim), (4.2.3)
where
∑





combinations of m distinct elements
(Xi1, . . . , Xim) from the sample (1, . . . , n). A Borel function h(·) is called a kernel func-
tion which is symmetric. In Hoeffding’s theorem, the variance of the U-statistics given
by definition 4.2.3 with E[h(X1, . . . , Xm)]
















ζk = V ar[hk(X1, ..., Xk)].
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An important Corollary from Hoeffding’s theorem is developed as
m2
n




We apply the Hájek projection theory and Hoeffding’s decomposition of U statistics (Van














(Xi, ηi, Yi, t0) + op(1),
where accounting for permutation symmetry of U statistics, we can write I
Ṽ US(t0)
as





i ̸=j ̸=k ̸=p ̸=q ̸=r
(Ψijkpqr(t0) + Ψjikpqr(t0) + Ψjkipqr(t0) + Ψjkpiqr(t0)
+Ψjkpqir(t0) + Ψjkpqri(t0)),
corresponding to its conditional expectation on the random vector (Xi, ηi, Yi),
I
Ṽ US
(Xi, ηi, Yi, t0) = E(Ψijkpqr(t0) + Ψjikpqr(t0) + Ψjkipqr(t0) + Ψjkpiqr(t0) + Ψjkpqir(t0)
+Ψjkpqri(t0) | (Xi, ηi, Yi)).
As a centered projection,E(I
Ṽ US
(Xi, ηi, Yi, t0)) = 0.










(Xi, ηi, Yi, t0)
2.
Weak convergence for Ṽ US(t0) over t0 ∈ [ν1, ν2] follows naturally.
One exciting contribution associated with our development of this methodology is that we
have implemented R code in estimating the variance of Ṽ US(t0). The matrix operations
are well formulated in R program based on their mathematical expressions including
martingale process for censoring and projection theory of U-statistics with a 6-degree
kernel function. The R codes are available once this research-related paper is accepted,
with which those interested users can directly obtain the estimator as well as its estimated
standard error without time-consuming bootstrapping.












5.0 TIED SCORES IN BIOMARKER AND HYPERVOLUME UNDER THE
ROC MANIFOLD FOR HIGH-DIMENSIONAL OUTCOMES
5.1 ADAPTION OF TIED SCORES IN THE BIOMARKER
We often encounter ties in a biomarker, for example it is rounded to nearest integers. To
account for ties in the biomarker, we modify the formula of V US in definition (2.3.1) by
replacing I(Yi < Yj < Yk) with a I(Yi < Yj < Yk) +
1
2
I(Yi < Yj = Yk) +
1
2




I(Yi = Yj = Yk), similarly to the ideas in Wang and Cheng (2014). With the
linear interpolation in the biomarker, the asymptotic properties still hold such as uniform
consistency and weak convergence. The weights correspond to how the tied scores can
contribute in predicting outcome events with a half probability when there are two tied scores,
or contribute with one sixth probability when Yi, Yj, Yk appear to be tied simultaneously.
Note that the ties occurring in the same disease status have no impact on their concordance
association.
With respect to V̂ US in handling tied scores in a biomarker, we can obtain insight
through a geometry exercise in ROC curve (Horton, 2016). We observe that the ROC curve
is an exact step function of an ordered biomarker when there are no ties. Either sensitivity
or specificity changes when the ordered biomaker moves from one value to the next, as a
unique value of the biomarker is associated with either a case or a control. AUC is to
summarize accuracy by adding up rectangles corresponding to the area under ROC curve
while Y moves through all possible values in order. However, in the presence of tied scores
in the biomarker, when a single tied score is associated with both cases and controls, it
leads to change of sensitivity and specificity simultaneously as the biomarker moves to the
next value, causing a sloped line segment in the ROC curve. Thus, the AUC can be under-
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or over-estimated depending on how tied scores affect concordance between the underneath
true continuous scores and their outcomes. Excitingly, the practice in AUC can be carried
over to our proposed VUS. Again the volume under the ROC surface can be under- or over-
estimated depending on how tied scores affect concordance (discordance) relationships. In
real clinical studies, it is reasonable to assume that tied records appear in a random pattern
without any systematic trend. So V̂ US is robust against tied scores in a biomarker. Later
we show through simulations by rounding Y into tied scores that the proposed Ṽ US and
V̂ US can handle a tied biomarker well.
To better illustrate the phenomenon of a tied biomarker affecting AUC, we provide an
example of a two-category outcome (1 = diseased group and 0 = healthy group). We have a
sample of 20 subjects with their biomarkers Y taking distint values (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15, 16, 17, 18, 19, 20) in order, which correspond to 20 binary outcomes (1, 1, 1, 1, 0,
1, 1, 0, 1, 0, 1, 0, 1, 0, 0, 1, 0, 0, 0, 0). By assuming the lower values of Y indicating the greater
likelihood of being diseased, it leads to an estimated concordance association AUC 0.83.
Then, we examine how the tied scores in the biomarker affect AUC. First, we replace the
scores of Y at positions 9 and 10 with their average 9.5. Note that the pair of untied scores
in positions 9 and 10 associated with a case and a control, which manifests a concordance
between the pair of markers and their outcomes. As a consequence, the tied scores reduce the
value of AUC to 0.825 since the ties diminish the concordance association, which attenuate
sensitivity and specificity correspondingly. Next, we replace the scores of Y at positions 8
and 9 with their average 8.5, where the two untied scores are associated with a control and
a case respectively, showing a discordance relationship. Therefore, the resulting AUC from
tied markers increases to 0.835 due to the tied scores covering the discordance relationship.
The following table 5.1 shows the associations of disease status and the original untied scores
vs. replaced tied scores under those two scenarios affecting the estimation of AUCs in details.
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Table 5.1: Untied scores vs. tied scores in biomarker affecting estimated AUC (Scenario 1 =
Replace with ties in Y to mask original concordance relationship; Scenario 2 = Replace with ties
in Y to mask original discordance relationship)




Ties scores in Y Ties scores in Y
(Class 1: T ≤ t0; (Scenario 1) (Scenario 2)
Class 0: T > t0)
1 1 1 1
1 2 2 2
1 3 3 3
1 4 4 4
0 5 5 5
1 6 6 6
1 7 7 7
0 8 8 8.5
1 9 9.5 8.5
0 10 9.5 10
1 11 11 11
0 12 12 12
1 13 13 13
0 14 14 14
0 15 15 15
1 16 16 16
0 17 17 17
0 18 18 18
0 19 19 19
0 20 20 20
Estimated AUC 0.83 0.825 0.835
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Figure 5.1 displays the ROC curves from the untied scores and tied scores and how the
estimated AUC changes by affecting sensitivity and specificity. More specifically, the three
figures plot sensitivity (TPR) vs 1-specificity (FPR) in terms of untied scores and tied scores
that mask the original concordance (or discordance) relationship to their outcome events.
The top left one is the ROC curve from untied scores, the top right is the ROC curve from
tied scores to mask the original strength of discordance, and the bottom left one is the ROC
curve from tied scores to mask the original strength of concordance. Note that the spaces
highlighted in red represent the affected sensitivity and specificity where a tied biomarker is













































































Figure 5.1: ROC curves from untied scores, tied scores which mask the original strength of discor-
dance, and tied scores which mask the original strength of concordance
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Furthermore, we take another example to illustrate the three-dimensional ROC surface.
By analogy, we generate continuous, untied scores of Y from 1 to 30 along with their associ-
ated outcome events. The tied scores were generated by replacing the scores at positions 7,
8, and 9 with the same score 8.5, where the original scores of Y are in a concordance with
the outcome statuses. By contrast, the tied scores by replacing the scores in positions 9, 10,
and 11 with 10.5 are generated accounting to the original discordance relationship. Table
5.2 shows the estimated V̂ USs from the tied scores are affected by the original concordance
and discordance relationships of the underneath untied scores to their outcomes.
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Table 5.2: Untied scores vs. tied scores in biomarker affecting estimated VUS (Scenario 1 = Replace
with ties in Y to mask original concordance relationship; Scenario 2 = Replace with ties in Y to





Ties scores in Y Ties scores in Y
(Class 1: T ≤ t0, ϵ = 1; (Scenario 1) (Scenario 2)
Class 2: T ≤ t0, ϵ = 2;
Class 3: T > t0 )
1 1 1 1
1 2 2 2
1 3 3 3
1 4 4 4
1 5 5 5
1 6 6 6
1 7 8.5 7
2 8 8.5 8
3 9 8.5 10.5
2 10 10 10.5
1 11 11 10.5
1 12 12 12
2 13 13 13
2 14 14 14
2 15 15 15
2 16 16 16
1 17 17 17
3 18 18 18
2 19 19 19
2 20 20 20
2 21 21 21
3 22 22 22
2 23 23 23
3 24 24 24
3 25 25 25
3 26 26 26
3 27 27 27
3 28 28 28
3 29 29 29
3 30 30 30
Estimated VUS 0.698 0.693 0.707
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5.2 GENERALIZATION TO HUM IN MULTI-WAY ORDINAL OUTCOME
EVENTS
It is straightforward to extend the concept of ROC surface and volume under ROC surface for
three-category outcome events to multi-way ROC analysis (Scurfield,1998) and hypervolume
under the ROC manifold (HUM).
In exploring a medical progression with M-category ordinal outcome events, where M >
3, we have M-1 sequentially progressive disease statuses, as compared to healthy controls
which is denoted as disease status M. Analogously, HUM corresponds to a probability that
the biomarker values and the ordinal outcome events are in concordance. Let Y1,Y2, . . . ,YM
denote the biomarkers from the subjects each from one of the M disease categories corre-
sponding to T1 ≤ t0, ϵ1 = 1,T2 ≤ t0, ϵ2 = 2, . . . ,TM > t0 respectively. We have the
relationship
HUM = P (Y1 < Y2 < · · · < YM
∣∣T1 ≤ t0, ϵ1 = 1,T2 ≤ t0, ϵ2 = 2, · · · ,TM > t0).
Also, subject to independent right-censoring C, we observe X = min(T,C) and η =
I(T ≤ C)ϵ.To account for the data with independent censoring, the IPCW-adjusted H̃UM(t0)





2 · · ·
∑
M
I(X1 ≤ t0, η1 = 1,X2 ≤ t0, η2 = 2, . . . ,XM > t0,Y1 < Y2 < · · · < YM)
Ĝ(X1)Ĝ(X2) . . . Ĝ(t0)∑
1
∑
2 · · ·
∑
M
I(X1 ≤ t0, η1 = 1,X2 ≤ t0, η2 = 2, . . . ,XM > t0)
Ĝ(X1)Ĝ(X2) · · · Ĝ(t0)
.
Heuristically, correct classification probability can be used as a building component in
constructing HUM. Let FY|m(y) denote the conditional CDF of Y given the subjects in the
mth class, where m ∈ (1, . . . ,M). Similarly, in order to assess the degree of accuracy on the
biomarker’s ability in predicting the M-catogory events outcomes and in accordance with
M − 1 threshold points (c1, c2, · · · , cM−1) with c1 < c2 < · · · < cM−1 from the distribution
of the biomarker Y, we assign a subject to Class 1 if their biomarker Y ≤ c1, to Class 2
if c1 < Y ≤ c2,..., to Class M-1 if cM−2 < Y ≤ cM−1,and to Class M for the remaining.
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The correct classification probabilities (CCPs) for the subjects experiencing each of the M-
category events by t0 arw defined as:
CCP1 = P (Yi ≤ c1|Ti ≤ t0, ϵi = 1) = FY|1(c1),
CCP2 = P (c1 < Yi ≤ c2|Ti ≤ t0, ϵi = 2) = FY|2(c2)− FY|2(c1),
...
CCPM = P (Yi > cM−1|Ti > t0) = 1− FY|M(cM−1),
As a consequence, the corresponding FY|m(y)s are used for mathematical expressions for each
of the CCPs.












In the M-dimension space, a domain of ROC manifold can be expressed as:
Q(u) = 1− FY|M(cM−1). (5.2.1)
Akin to a three-category competing risks setting, F̂Y|m, m = 1, · · · ,M , are obtained from
the nonparametric estimators for bivariate CIF, where continuous Y is treated as a special
case of survival data without censoring, and for univariate CIF respectively. Furthermore,
plugging in those estimated F̂Y|m(y) in into definition 5.2.1, we derive Q̂.










Q̂(u)du1du2 · · · duM−1.
For a M-class outcome, HUM is equal to 1/M ! when we conduct a random test without
any predictive power where M ! = M × (M − 1)× · · · × 1.
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The asymptotic properties of ĤUM(t0) and H̃UM(t0) can be established the same as
those in V̂ US(t0) and V̂ US(t0). Heuristically, the previous discussion on handling tied scores
in the biomarker for three categorical outcome events is straightforward to be carried over




In this section, we conducted simulations to assess the performance of our proposed es-
timators of VUS from the two different estimating methods. We generated a continu-
ous variable for a biomarker through a uniform distribution as Y ∼ uniform(0, U ], and
specified two points (c1, c2) where 0 < c1 < c2 < U , breaking up Y into three segments
(0, c1], (c1, c2], (c2, U ] with equal sample sizes in each subset. We generated 3 sets of pairs
where Td ∼ e−(βd+γd) and ϕd ∼ bin( βdβd+γd ), d = 1, 2, 3, representing the time to events and
the types of events, corresponding to the 3 subsets of Y , where ϵ = I(ϕ = 1) + 2I(ϕ = 0).
The parameters βd and γd determine the underlying association between the cause-1 event,





where λ1 and λ2 are the hazard rates of the cause-1 event and the cause-2 event, respec-
tively. In the following simulations, we always assigned U = 20 and let c1 = 5, c2 = 10 to
break the biomarker Y into the 3 segments (0, 5], (5, 10] and (10, 20]. Also, we generated an
independent censoring C from a uniform distribution.
We evaluated the performance of the estimators under various scenarios, including three
setting of predictive power of the biomarker to the competing events using three scenarios.
The first scenario represented a strong predictive association between the two by defining
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β1 = 50 and γ1 = 3 when Y ∈ (0, 5]; β2 = 3 and γ2 = 50 when Y ∈ (5, 10]; and β3 = 1
and γ3 = 1 when Y ∈ (10, 20]. Hence, the ratio of occurrences of the cause-1 event to the
cause-2 event was 16.7 when the values of biomarker Y ∈ (0, 5]. Then the ratio was reversed
in favor of occurrences of the cause-2 event when Y increased to (5, 10], followed by both
events declining to the same low rate when Y was greater than 10. The second scenario
simulated a moderate predictive association by defining β1 = 8.0 and γ1 = 3.5; β2 = 3.5
and γ2 = 3.0; and β3 = 1.0 and γ2 = 2.0. The third scenario was for the null hypothesis
of a completely random test. We specified βd = 3 and γd = 3, d = 1, 2, 3, with the same
hazard rates between the cause-1 event and the cause-2 event across the full spectrum of
Y . For each strength of predictive power, we considered three different t0s, where t0s were
selected with 25− 30%, 65− 70%, and 75− 85% subjects experienced the events. Also, the
censoring rates were 15% and 30% generated from uniform distributions, respectively. We
chose sample size = 150, 300 with 1000 simulated datasets for each combination of scenarios.
We computed both Ṽ US and V̂ US for each simulated dataset. The estimated IPCW ad-
justed standard errors σ̂
Ṽ US
were calculated based on the developed formula. For V̂ US(t0),
its variance can be estimated from the influence function in Theorem 3.1. However, the eval-
uation of the influence function is rather complicated. Bootstrapping with 250 replications
was used instead to the estimate standard error σ̂
Ṽ US
. We compared the resulting estima-
tors with the true VUS, which was derived based on a large sample without independent




(empirical standard error), ASE
Ṽ US
(model-based standard error), and CP
Ṽ US
(coverage
probability) for Ṽ US(t0), as well as the bias BV̂ US, ESEV̂ US (empirical standard error),
BSE
V̂ US
(bootstrap standard error), and CP
V̂ US
(coverage probability) for V̂ US(t0).
To assess tied scores in a biomarker, we tested under the scenarios above with a sample
size of 300. We generated tied scores of the biomarker on an discrete scale by rounding
Y ∈ (0, 5] or (10, 20] to the nearest 0.1, and rounding Y ∈ (5, 10] to the nearest 0.2. This
design emulated real clinical studies for some ranges of values with higher frequencies than
others by their biological natures.
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6.2 SIMULATION RESULTS
Table 6.1 outlined the simulation results combining all scenarios for sample size = 300 with
1000 replications. As expected, the mean values from both Ṽ US and V̂ US were barely
different from the true values, and their coverage rates were close to the nominal level 0.95.
The model-based standard error, the bootstrap standard error, and the empirical stanard
errors from the two estimators all agree with each other. When there is no association
between the biomarker and the three disease statuses under the null hypothesis, the means
of the two estimators barely deviate from the true value 0.167 and the coverage rates are
very close to 95%. Since a type I error occurs when a true null hypothesis is rejected, the
simulated results ensure the type I error from a two-sided test at 0.05.
An interesting phenomenon was discovered in our simulation procedure. When compar-
ing the estimators of Ṽ US and V̂ US from a single simulated dataset (data not shown here),
the discrepancies between the two were more apparent under moderate association or non-
informative association than under strong association, even though their means were always
very close to each other across different associations. For example, the discrepancy between
the two estimates from 1000 individual datasets that we simulated with 30% censoring could
be as high as 26% in moderate association at t0 = 0.3, and the maximum discrepancy be-
tween the two estimates was 18% for the no association case at t0 = 0.3. In contrast, the
discrepancy was only as much as 9% under the strong association at t0 = 0.05.
In addition, the resulting estimators from both proposed methods demonstrated satisfac-
tory behaviors in the simulation results in term of unbiasness and nominal level of coverage
rates when n = 150 in Table 6.2. The standard errors from simulations of sample size of 150
were approximately
√
2 times of those from sample size of 300, indicating that the standard
deviation goes to 0 as n → ∞. Also, simulation results with tied scores in the biomarker
(Table 6.3) were satisfactorily similar to those without tied scores. The proposed estimation
using either approach is robust against tied scores in a biomarker if the tied biomarker is
not systematic in favor of concordance or discordance.
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Table 6.1: Simulation results of the two VUS estimators for the untied scores in biomarker with sample size n=300 (1000 replications)
Ṽ US V̂ US
t0 Cen rate True AUC BṼ US ESEṼ US ASEṼ US CPṼ US BV̂ US ESEV̂ US BSEV̂ US CPV̂ US
Strong predicative power
0.01 30% 0.542 0.002 0.032 0.034 95.4% 0.004 0.034 0.036 96.3%
0.05 30% 0.790 0.002 0.037 0.037 95.0% 0.004 0.039 0.038 95.0%
0.20 30% 0.760 0.002 0.037 0.040 95.4% -0.010 0.040 0.042 95.5%
0.01 15% 0.542 0.000 0.030 0.034 96.2% 0.004 0.031 0.034 96.1%
0.05 15% 0.790 0.001 0.037 0.036 94.6% 0.001 0.038 0.037 94.5%
0.20 15% 0.760 0.000 0.032 0.035 95.8% -0.007 0.033 0.037 96.4%
Moderate predictive power
0.05 30% 0.296 0.001 0.038 0.038 94.8% 0.007 0.039 0.039 95.5%
0.20 30% 0.355 0.001 0.036 0.037 95.6% 0.005 0.037 0.039 96.2%
0.30 30% 0.382 0.001 0.046 0.044 93.0% -0.001 0.038 0.039 95.7%
0.05 15% 0.296 0.000 0.038 0.037 94.2% 0.006 0.039 0.039 95.4%
0.20 15% 0.355 0.002 0.035 0.034 94.4% 0.004 0.035 0.035 94.7%
0.30 15% 0.382 0.001 0.036 0.038 96.2% 0.002 0.037 0.039 95.5%
No predictive power
0.05 30% 0.167 0.000 0.032 0.030 93.8% 0.006 0.032 0.033 95.4%
0.20 30% 0.167 0.003 0.029 0.027 95.0% 0.003 0.028 0.029 95.5%
0.30 30% 0.167 0.001 0.038 0.036 94.2% 0.004 0.035 0.033 94.1%
0.05 15% 0.167 0.000 0.032 0.030 94.6% 0.003 0.032 0.033 95.7%
0.20 15% 0.167 -0.001 0.024 0.024 95.2% 0.005 0.025 0.027 95.4%
0.30 15% 0.167 0.000 0.031 0.029 94.6% 0.001 0.031 0.030 94.3%
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Table 6.2: Simulation results of the two VUS estimators for the untied scores in biomarker with sample size n=150 (1000 replications)
Ṽ US V̂ US
t0 Cen rate True AUC BṼ US ESEṼ US ASEṼ US CPṼ US BV̂ US ESEV̂ US BSEV̂ US CPV̂ US
Strong predicative power
0.01 30% 0.542 0.002 0.046 0.050 96.2% 0.000 0.047 0.048 95.1%
0.05 30% 0.790 0.005 0.052 0.052 94.4% -0.005 0.058 0.055 94.8%
0.20 30% 0.760 0.000 0.055 0.058 96.0% -0.018 0.062 0.060 94.3%
0.01 15% 0.542 0.003 0.044 0.049 96.2% 0.001 0.045 0.045 94.6%
0.05 15% 0.790 0.001 0.049 0.050 95.2% -0.003 0.052 0.050 94.3%
0.20 15% 0.760 -0.001 0.046 0.051 96.0% -0.011 0.047 0.049 96.1%
Moderate predictive power
0.05 30% 0.296 0.001 0.055 0.055 94.6% 0.001 0.056 0.057 94.6%
0.20 30% 0.355 0.003 0.055 0.053 93.8% 0.001 0.057 0.055 95.7%
0.30 30% 0.382 0.003 0.063 0.062 94.8% -0.002 0.067 0.063 94.3%
0.05 15% 0.296 0.002 0.053 0.054 95.6% 0.003 0.053 0.051 94.5%
0.20 15% 0.355 0.001 0.048 0.049 94.8% 0.005 0.049 0.051 95.9%
0.30 15% 0.382 -0.005 0.053 0.054 94.6% -0.004 0.054 0.056 95.6%
No predictive power
0.05 30% 0.167 -0.001 0.046 0.043 93.8% 0.002 0.046 0.047 95.1%
0.20 30% 0.167 0.000 0.039 0.038 94.6% 0.001 0.039 0.038 95.3%
0.30 30% 0.167 0.001 0.051 0.051 95.2% -0.001 0.047 0.048 94.5%
0.05 15% 0.167 0.001 0.042 0.043 95.4% 0.005 0.042 0.044 95.4%
0.20 15% 0.167 -0.001 0.036 0.036 95.6% 0.001 0.036 0.037 95.1%
0.30 15% 0.167 -0.002 0.044 0.042 94.6% 0.000 0.042 0.041 95.1%
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Table 6.3: Simulation results of the two VUS estimators for the tied scores in biomarker with sample size n=300 (1000 replications)
Ṽ US V̂ US
t0 Cen rate True AUC BṼ US ESEṼ US ASEṼ US CPṼ US BV̂ US ESEV̂ US BSEV̂ US CPV̂ US
Strong predicative power
0.01 30% 0.542 -0.001 0.033 0.036 96.6% -0.005 0.033 0.037 96.6%
0.05 30% 0.790 -0.001 0.038 0.037 93.6% -0.006 0.041 0.040 94.3%
0.20 30% 0.760 0.000 0.034 0.038 96.2% -0.016 0.037 0.039 95.9%
0.01 15% 0.542 0.002 0.030 0.034 97.1% -0.003 0.032 0.037 96.7%
0.05 15% 0.790 0.003 0.035 0.035 95.2% 0.003 0.037 0.036 94.1%
0.20 15% 0.760 0.001 0.030 0.035 97.6% -0.011 0.034 0.037 96.1%
Moderate predictive power
0.05 30% 0.296 -0.001 0.038 0.039 95.7% 0.002 0.038 0.038 95.1%
0.20 30% 0.355 0.000 0.037 0.037 95.0% 0.002 0.039 0.038 94.1%
0.30 30% 0.382 0.002 0.044 0.044 95.1% -0.001 0.046 0.045 94.1%
0.05 15% 0.296 0.001 0.037 0.037 94.1% 0.003 0.038 0.038 95.2%
0.20 15% 0.355 0.000 0.033 0.034 96.2% 0.001 0.035 0.034 94.7%
0.30 15% 0.382 0.001 0.038 0.038 94.2% -0.002 0.040 0.040 95.3%
No predictive power
0.05 30% 0.167 0.003 0.031 0.030 93.8% 0.006 0.031 0..031 94.5%
0.20 30% 0.167 0.000 0.027 0.027 94.5% 0.003 0.027 0.027 94.7%
0.30 30% 0.167 -0.003 0.033 0.034 94.6% 0.001 0.034 0.033 94.1%
0.05 15% 0.167 -0.001 0.030 0.029 94.1% 0.004 0.030 0.030 94.7%
0.20 15% 0.167 -0.001 0.024 0.024 94.6% 0.003 0.025 0.025 94.9%
0.30 15% 0.167 -0.001 0.029 0.029 94.0% 0.000 0.030 0.029 94.7%
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6.3 DISCRIMINATIVE ABILITY OF VUS CORRESPONDING TO AUC
To address the discriminative ability of VUS, Table 6.4 presents the accuracy of a diagnostic
test using the biomarker Y to the competing events with five predictive associations. We
carry over the three scenarios in aforementioned simulation design, along with two additional
predictive associations representing the predictive power from very strong, strong, moderate,
weak, to none. The simulated datasets are generated with the parameters βd and γd, for
d = 1, 2, 3 which determine the underlying association between the cause-1 event, the cause-2
event and the biomarker Y , as well as t0s which are chosen to classify the disease statuses
without censoring for sample size 300. We reported Ṽ US, as well as corresponding AUC1,3
(by comparing the cause-1 cases to the healthy controls), AUC2,3 (by comparing the cause-2
cases to the healthy controls), and AUC1,2 (by comparing the cause-1 cases to the cause-2
cases). All of the estimation of AUC were derived using the R package “pROC” due to the
simulated data without censoring. From those reported Ṽ US, and corresponding AUCs,
VUS, ranging from 0.167-1, is a metric reflecting the summary accuracy of the three AUC.
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Table 6.4: Discriminative ability of VUS associated with AUC
Predictive
power
Parameter t0 Ṽ US AUC1,3 AUC1,2 AUC1,2
Very
strong
β1 = 50.0; β2 = 3.0; β3 = 1.0;
γ1 = 3.0; γ2 = 50.0; γ2 = 1.0
0.05 0.874 0.971 0.935 0.936
Strong β1 = 22.5; β2 = 3.5; β3 = 0.4;
γ1 = 3.5; γ2 = 3.0; γ2 = 1.8
0.30 0.518 0.927 0.723 0.779
Moderate β1 = 8.0; β2 = 3.5; β3 = 1.0;
γ1 = 3.5; γ2 = 3.0; γ2 = 2.0
0.30 0.418 0.851 0.729 0.657
Weak β1 = 4.5; β2 = 3.2; β3 = 1.5;
γ1 = 3.5; γ2 = 3.0; γ2 = 1.8
0.30 0.316 0.76 0.723 0.544
None β1 = 3.0; β2 = 3.0; β3 = 3.0;
γ1 = 3.0; γ2 = 3.0; γ2 = 3.0
0.30 0.173 0.513 0.507 0.517
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7.0 REAL STUDY EXAMPLES
7.1 THE MYHAT DATA
We applied our proposed methods to the cohort data of the Monongahela-Youghiogheny
Healthy Aging Team (MYHAT). A random community sample with normal cognitive func-
tion to mild cognitive impairment was recruited beginning in year 2006, stratified by three
age groups 65-74, 75-84, and 85+ years. The participants were followed prospectively for up
to 9 annual visits to assess their cognitive decline and onset of dementia. The participants
cognitive status was evaluated at baseline and the follow-up visits using the Clinical Demen-
tia Rating (CDR). We classified CDR ≥ 0.5 as the occurrence of cognitive impairment or
dementia, and death as the other competing event. Death was treated as a worse medical
condition. There were 1982 participants who met the study eligibility criteria and completed
their cognitive test battery in follow-ups. For homogeneity, we removed the participants who
were measured with CDR ≥ 0.5 at baseline. Also, we excluded one deceased participant
whose deceased date was prior to its baseline date, and our final analytical sample included
1412 participants.
We are interested in testing whether the five cognitive scores targeting in domains of
attention, executive function, language, memory and visuospatial at baseline, can predict
subsequent cognitive impairment and death within a 5 or 7 years. The cognitive scores were
standardized by subtracting the age and sex adjusted population means and dividing by their
standard deviations. According to the age-stratified design, our analysis was conducted
for the three age subgroups, where we renamed the three age groups 65-74, 75-84, and
85+ years as young, middle and old age groups respectively. The frequencies of observed
numbers of deaths, cognitive impairment, event-free survivors and censoring participants at
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the selected t0 of 5 years were reported in Table 7.1. Note that censored participants were
used for estimation of weights in the IPCW method, who were not accounted for calculating
percentages within the age groups.
We compared the distributions of IPCW-adjusted cognitive testing scores to their un-
weighted scores for young, middle and old age groups by the disease status of death, cognitive
impairment, and cognitive-normal survivors at t0 = 5 years in Tables 7.2, 7.3, 7.4. According
to space limitation, we put Atten(tion), Execu(tive function), Langu(age), Memor(y), and
Visuo(spatial) representing the five cognitive testing domains. From either methods, The
distributions of those five cognitive tests didn’t exhibit much discrimination trends across
the three disease statuses using either methods, though IPCW-adjusted distributions were
more directly related to the Ṽ US in handling missingness due to right censoring. Moreover,
we presented the estimated density plots for the five domain scores for those who experienced
cognitive impairment (green dash lines), and those who died (red solid lines), as well as those
who were alive and cognitively normal (blue dotted lines) after 5 years of follow up, in the
MYHAT young, middle, old age groups in Figures 7.1, 7.2, and 7.3 respectively. In account-
ing for missingness due to right censoring before 5 years, we adopted the IPCW method
by weighting domain scores for each disease status as in equation (4.1.1), and then applied
the kernel smoothing method to generate the density plots using the R package “sm.” In
general, the three density curves were in general close to each other in young and middle age
groups, indicating poor separability of the disease progression in five years based on those
domain scores at baseline. However in the old age group, the three density curves looked
more discriminatory than the two younger groups, although they still displayed significant
overlaps in terms of areas under those three curves.
The VUSs from the two approaches, as well as two AUC estimates for each of the
competing events (death or cognitive impairment) as compared to the event-free survivors
were computed in Table 7.5, where the AUC was derived using the R package “timeROC”.
In general, the 5 cognitive test scores were shown to have poor predictive power in predicting
cognitive impairment and death since the estimators from both methods were relatively low,
which were considerably consistent with the results of AUCs. Along with what we have
observed in the three Figures, we conclude that the five domain scores at baseline exhibit
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poor predictive power in discriminating the sequence of the competing events. Nevertheless,
VUSs allow the measurement of the global concordance between the continuous cognitive
test scores and the sequence of cognitive impairment and death.
Moreover, the estimated VUSs from the two approaches are reasonably close and most
discrepancies are less than one standard deviation. This is consistent with what we have
discovered in simulations that the two estimators differ more in weaker association. We
repeated the analyses at t0 = 7 years and observed similar results. Interestingly, we observe
stronger associations between baseline domain scores and disease progression in older groups
at both time points, despite that the predictive power is generally weak. For example,
estimated Ṽ US for baseline executive function showed increasing predictive power with age
as 0.176, 0.253, 0.303 for aged 65-74, 75-84, and 85+ years in the 5 years window.
Table 7.1: Frequencies of death, cognitive impairment, survivor and censored participants in each
of the three age subgroups in MYHAT study (t0 = 5 years)
Age group Death Dementia Survivor Censored
Young (n=539) 40 (9.4%) 37 (8.7%) 349 (81.9%) 113
Middle (n=654) 77 (15.3%) 131 (25.9%) 297 (58.8%) 149
Old (n=219) 64 (34.6%) 60 (32.4%) 61 (33.0%) 34
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Table 7.2: Unweighted vs. IPCW-weighted distributions of cognitive testing scores in young age group by event status (t0 = 5 years)












Event Status = Death
Atten -2.245 -0.135 0.245 0.682 1.747 -2.599 -0.151 0.259 0.778 2.212
Execu -1.443 -0.093 0.212 0.626 1.486 -1.562 -0.108 0.265 0.743 1.733
Langu -1.531 0.131 0.524 0.752 1.494 -1.961 0.158 0.624 0.826 1.734
Memor -1.044 -0.027 0.533 0.902 1.313 -1.344 -0.025 0.628 0.994 1.604
Visuo -1.752 -0.262 0.430 1.121 2.505 -1.894 -0.241 0.485 1.269 3.201
Event Status = Cognitive Impairment
Atten -1.731 -0.186 0.361 0.783 1.747 -1.785 -0.229 0.424 0.869 1.908
Execu -1.066 -0.244 0.202 0.777 1.703 -1.246 -0.289 0.212 0.793 1.991
Langu -1.383 -0.232 0.328 0.734 1.204 -1.617 -0.275 0.383 0.769 1.271
Memor -1.435 -0.434 0.012 0.591 1.449 -1.677 -0.459 0.013 0.603 1.601
Visuo -1.965 -0.900 0.004 1.015 2.718 -2.412 -0.032 0.005 1.083 3.179
Event Status = Survivors
Atten -1.295 -0.010 0.433 0.894 2.780 -1.673 -0.013 0.559 1.155 3.591
Execu -1.230 0.119 0.498 0.889 2.912 -1.589 0.156 0.643 1.141 3.761
Langu -3.132 0.231 0.555 0.839 1.770 -0.405 0.303 0.716 1.083 2.286
Memor -1.475 0.229 0.615 0.979 2.015 -1.905 0.297 0.794 1.262 2.603
Visuo -2.603 -0.156 0.376 1.121 3.462 -3.347 -0.201 0.484 1.442 4.452
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Table 7.3: Unweighted vs. IPCW-weighted distributions of cognitive testing scores in middle age group by event status (t0 = 5 years)












Event Status = Death
Atten -1.386 -0.534 -0.069 0.361 1.138 -1.504 -0.611 -0.081 0.431 1.425
Execu -2.686 -0.566 -0.081 0.298 1.275 -2.864 -0.648 -0.094 0.374 1.281
Langu -2.207 -0.209 0.086 0.486 1.176 -2.461 -0.227 0.106 0.609 1.315
Memor -1.633 -0.439 -0.042 0.411 1.303 -1.889 -0.519 -0.053 0.446 1.481
Visuo -1.752 -0.688 -0.049 0.376 1.334 -2.359 0.779 -0.063 0.457 1.542
Event Status = Cognitive Impairment
Atten -1.766 -0.572 -0.050 0.470 1.648 -2.097 -0.637 -0.053 0.567 2.087
Execu -1.689 -0.551 -0.106 0.254 2.697 -1.847 -0.641 -0.115 0.272 3.416
Langu -1.850 -0.423 0.055 0.348 1.538 -1.918 -0.439 0.059 0.429 1.948
Memor -1.976 -0.605 -0.232 0.160 1.343 -2.034 -0.683 -0.251 0.191 1.831
Visuo -2.071 -0.794 -0.049 0.376 2.611 -2.285 -0.914 -0.065 0.408 3.578
Event Status = Survivors
Atten -1.618 -0.397 0.029 0.541 2.244 -2.251 -0.552 0.041 0.752 3.006
Execu -2.151 -0.166 0.257 0.579 2.367 -2.988 -0.231 0.357 0.804 3.287
Langu -1.727 -0.080 0.286 0.665 1.494 -2.398 -0.111 0.398 0.924 2.074
Memor -1.372 -0.058 0.274 0.664 1.955 -1.908 -0.081 0.382 0.923 2.719
Visuo -1.752 -0.368 0.164 0.696 3.037 -2.426 -0.437 0.227 0.964 4.206
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Table 7.4: Unweighted vs. IPCW-weighted distributions of cognitive testing scores in old age group by event status (t0 = 5 years)













Event Status = Death
Atten -1.698 -1.020 -0.565 0.066 1.325 -1.945 -1.195 -0.619 0.045 1.452
Execu -2.783 -0.942 -0.558 -0.095 1.042 -3.487 -1.066 -0.647 -0.115 1.088
Langu -2.924 -0.845 -0.305 0.022 1.052 -3.531 -0.889 -0.354 0.021 1.271
Memor -1.463 -0.936 -0.513 -0.147 1.433 -1.671 -0.999 -0.584 -0.158 1.795
Visuo -1.752 -0.900 -0.475 0.057 1.441 -2.121 -0.987 -0.493 0.058 1.743
Event Status = Cognitive Impairment
Atten -1.982 -0.572 -0.039 0.509 1.434 -2.335 -0.944 -0.511 0.255 1.689
Execu -1.346 -0.445 -0.140 0.346 1.862 -2.233 -0.721 -0.496 0.041 1.972
Langu -2.715 -0.431 -0.037 0.279 1.494 -2.934 -1.023 -0.428 0.029 1.067
Memor -1.446 -0.415 -0.064 0.560 1.333 -1.997 -1.185 -0.628 0.225 1.434
Visuo -2.177 -0.475 -0.049 0.376 1.547 -2.441 -1.362 -0.916 -0.147 1.573
Event Status = Survivors
Atten -1.982 -0.572 -0.039 0.509 1.434 -2.618 -0.756 -0.052 0.667 1.894
Execu -1.346 -0.445 -0.140 0.346 1.862 -1.773 -0.586 -0.185 0.455 2.453
Langu -2.715 -0.431 -0.037 0.279 1.494 -3.576 -0.568 -0.049 0.368 1.968
Memor -1.446 -0.415 -0.064 0.560 1.333 -1.905 -0.546 -0.084 0.738 1.756
Visuo -2.177 -0.475 -0.049 0.376 1.547 -2.897 -0.632 -0.065 0.501 2.058
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Figure 7.1: IPCW-adjusted distributions of five cognitive test scores in Young Age Group by disease
status in MAHAT study
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Figure 7.2: IPCW-adjusted distributions of five cognitive test scores in Middle Age Group by
disease status in MAHAT study
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Figure 7.3: IPCW-adjusted distributions of five cognitive test scores in Old Age Group by disease
status in MAHAT study
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Table 7.5: VUS and AUC of five cognitive testing scores at t0 = 5 years
age group Cognitve test Ṽ US (σ̂
Ṽ US
) Ṽ US (σ̂
V̂ US
) AUC1 (σ̂AUC1) AUC2 (σ̂AUC2)
Young Attention 0.190 (0.030) 0.170 (0.032) 0.581 (0.048) 0.538 (0.054)
Executive 0.176 (0.030) 0.151 (0.027) 0.623 (0.044) 0.594 (0.056)
Language 0.168 (0.030) 0.160 (0.033) 0.547 (0.049) 0.636 (0.051)
Memory 0.184 (0.036) 0.181 (0.037) 0.572 (0.051) 0.722 (0.046)
Visuosptial 0.139 (0.026) 0.146 (0.029) 0.510 (0.048) 0.591 (0.058)
Middle Attention 0.194 (0.022) 0.195 (0.021) 0.571 (0.036) 0.556 (0.031)
Executive 0.253 (0.027) 0.233 (0.026) 0.659 (0.035) 0.671 (0.029)
Language 0.199 (0.024) 0.175 (0.022) 0.589 (0.035) 0.637 (0.029)
Memory 0.234 (0.028) 0.221 (0.026) 0.656 (0.036) 0.750 (0.028)
Visuosptial 0.216 (0.024) 0.216 (0.031) 0.622 (0.037) 0.623 (0.032)
Old Attention 0.276 (0.037) 0.272 (0.033) 0.684 (0.048) 0.619 (0.051)
Executive 0.303 (0.039) 0.273 (0.038) 0.690 (0.047) 0.648 (0.050)
Language 0.228 (0.034) 0.225 (0.034) 0.633 (0.050) 0.633 (0.051)
Memory 0.255 (0.036) 0.248 (0.037) 0.730 (0.045) 0.695 (0.048)
Visuosptial 0.209 (0.033) 0.247 (0.038) 0.612 (0.053) 0.665 (0.053)
1. AUC1 compares deaths to healthy controls.
2. AUC2 compares cognitive impairment to healthy controls.
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7.2 THE PBC DATA
We next applied our methods to a well-known public dataset from the Mayo Clinical trial
of Primary Biliary Cirrhosis (PBC) of the liver. The trial was conducted between 1974
and 1984, and the analysis included 418 patients who met eligibility criteria with complete
data. Bilirubin is a prognostic biomarker commonly applied in PBC since cirrhosis causes
high bilirubin levels. In the PBC data, bilirubin was heavily tied especially at levels below 2
mg/dL. Here, we reversed bilirubin values using a reciprocal function in order to be consistent
with the direction in our definitions of VUS. The objective of the analysis was to determine
the time window by which bilirubin could reasonably predict liver transplant (cause-2) and
death (cause-1) events. Since liver transplants typically took place after 500 days of follow-up
while death occurred from day 41, we picked 5 time points as t0 = 1000, 1500, 2000, 2500, 3000
days.
The frequency of observed numbers of deaths, liver transplantation, event-free survivors
and censoring patients at the different selected t0 were reported in Table 7.6. As before,
the censored participants were used for estimation of weights in the IPCW method, and
we didn’t account them for percentages. We provided the unweighted and IPCW-adjusted
distributions of bilirubin across all selected times in Table 7.7. Based on the estimated
VUSs and AUCs (in Table 7.8), bilirubin presented an overall predictive power on both
events across those selected times, with highest discriminative power during 4-5.5 years.
Consistently, the three IPCW-adjusted density curves of the reciprocal bilirubin values for
those who died, had liver transplant, or survived without transplant were most separated
at t0 = 1500 days; see Figure 7.4 for details. As expected, the estimates were closer than
the ones in MYHAT study, as the associations between bilirubin and competing events were
generally stronger.
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Table 7.6: Frequencies of death, liver transplant, survivor and censored patients at different t0 in
PBC study (n=418).
t0 (days) Death Liver transplant Survivor Censored
1000 76 (18.5%) 7 (1.7%) 327 (79.8%) 8
1500 104 (29.1%) 14 (3.9%) 240 (67.0%) 60
2000 118 (37.7 %) 17 (5.4%) 178 (56.9%) 105
2500 134 (47.8%) 23 (8.2%) 123 (43.9%) 138
3000 143 (59.1%) 23 (9.5%) 76 (31.4%) 176
55
Table 7.7: Unweighted vs. IPCW-weighted distributions of bilirubin (transformed with a reciprocal function) at different t0 by event
status
Unweighted Distribution of Cognitive
Score
IPCW-weighted Distribution of Cogni-
tive Score









Event Status = Death
1000 0.036 0.086 0.211 0.389 1.667 0.036 0.086 0.211 0.395 1.667
1500 0.036 0.089 0.211 0.421 1.667 0.036 0.089 0.223 0.421 1.753
2000 0.036 0.107 0.233 0.450 1.667 0.036 0.113 0.248 0.491 1.753
2500 0.036 0.128 0.271 0.548 3.333 0.036 0.138 0.298 0.638 6.385
3000 0..036 0.137 0.286 0.590 3.333 0.036 0.141 0.313 0.769 6.385
Event Status = Liver Transplant
1000 0.164 0.205 0.313 0.369 0.833 0.164 0.205 0.315 0.372 0.833
1500 0.115 0.242 0.369 0.616 1.250 0.119 0.245 0.372 0.739 1.281
2000 0.115 0.286 0.323 0.588 1.250 0.119 0.296 0.364 0.676 1.281
2500 0.056 0.257 0.313 0.607 2.000 0.095 0.306 0.421 0.638 3.386
3000 0.056 0.257 0.313 0.607 2.000 0.095 0.306 0.421 0.718 3.386
Event Status = Survivors
1000 0.051 0.455 0.909 1.429 3.333 0.051 0.467 0.933 1.467 3.423
1500 0.056 0.526 1.000 1.429 3.333 0.069 0.651 1.237 1.767 4.124
2000 0.056 0.635 1.111 1.667 3.333 0.086 0.981 1.715 2.572 5.144
2500 0.069 0.691 1.111 1.429 3.333 0.135 1.345 2.164 2.782 6.491
3000 0.112 0.714 1.111 1.429 3.333 0.325 2.021 3.189 4.101 9.566
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Figure 7.4: IPCW-adjusted distributions of bilirubin (transformed with a reciprocal function) by
disease status at different t0 in PBC Study
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Table 7.8: VUS and AUC of bilirubin at t0= 1000, 1500, 2000, 2500, 3000 days.
t0 (days) Ṽ US (σ̂V̂ US) V̂ US (σ̂V̂ US) AUC1 (σ̂AUC1) AUC2 (σ̂AUC2)
1000 0.486 (0.045) 0.486 (0.047) 0.823 (0.027) 0.799 (0.050)
1500 0.510 (0.039) 0.499 (0.042) 0.856 (0.022) 0.780 (0.049)
2000 0.513 (0.039) 0.502 (0.038) 0.864 (0.022) 0.827 (0.040)
2500 0.416 (0.046) 0.411 (0.047) 0.820 (0.028) 0.816 (0.560)
3000 0.390 (0.046) 0.384 (0.047) 0.805 (0.031) 0.822 (0.058)
1. AUC1 compares deaths to healthy controls.
2. AUC2 compares liver transplant to healthy controls.
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8.0 CONCLUSIONS
In this dissertation we introduced the concept of the ROC surface and the associated volume
under the ROC surface (VUS) in measuring diagnostic accuracy of a continuous biomarker to
competing risks outcomes, where the samples were also subject to random censoring. Based
on two alternative aspects of viewing the VUS as the volume under the ROC surface that
is spanned by correct classification probabilities or the concordance between a continuous
biomarker and a sequence of competing events, we proposed two nonparametric estimators
of the VUS, and established their asymptotic properties and illustrated their performance
through simulations. We showed that even in the presence of tied biomarker values, the two
approaches provide consistent estimates of VUS for censored data of varying proportions.
Moreover, we applied the two VUS estimators to two study data sets, and the separate AUCs
for each event comparing the healthy survivors showed consistent results with the estimated
VUSs. Thus, the VUS provides a complementary global discriminatory metric for assessing
ordered events simultaneously.
Both estimators exhibit satisfactory properties given the results from various simulation
scenarios and real data analyses, however Ṽ US should outperform V̂ US for the following
reasons. First, the model-based standard errors are directly produced for Ṽ US given the
implemented R program, while the estimated standard errors of V̂ US are derived from
bootstrap. Second, Ṽ US is more reliable when subjects in each disease status categories
are substantially unbalanced. V̂ US is estimated according to summation over the uniform
squares with respect to approximation of the volume under ROC surface, which leads to the
resulting V̂ US lack of precision when there are much fewer subjects in the disease group. In
contrast, Ṽ US is more reliable to unbalance samples. Third, regarding the solutions of the
both estimators to handle tied scores in a biomarker, Ṽ US is modified with corresponding
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weights targeting in each specific tied score scenarios. V̂ US, in general, leads to an unbiased
estimator by assuming a random pattern of tied score, which causes overestimation and
underestimation of V̂ US washing off to each other. However, for a specfic sample, it exists
a potential in terms of overestimation (or underestimation) of V̂ US.
One important task in clinical decision making is to identify those subjects who will
develop a certain severity in their disease progression by a specific time window, thus pro-
viding targets for better treatment or prevention. The concept of the VUS allows projecting
a patient’s diagnostic biomarker onto three-stage disease progression. It is straightforward to
extend the metrics to higher dimensional outcomes by introducing multi-way ROC analysis
(Scurfield, 1996) and the hypervolume under the ROC manifold (HUM). The HUM can also
be estimated as a U-type statistic, as well as by integrating CCPs from multiple dimen-
sions. Large sample properties such as consistency and weak convergence still hold for the
estimated HUM, and the discussions on handling tied scores in a biomarker can be easily
carried over to HUM estimators.
Currently we included a single biomarker to predict a sequence of competing events. In
MYHAT study, we evaluated discriminatory power of the five cognitive test scores on cog-
nitive impairment and death stratified by age. It may be more informative in treating age
as a covariate rather than a stratified factor. To achieve this goal, we can fit semiparamet-
ric regression models as in Zheng et.al (2012). Moreover, if the competing events are not
sequential, the biomarker should not be a scaler, but rather a vector(Obuchowski, 2005).
Subjects are assigned to the disease status category with the highest probability given the
vector of risk factors, which is estimated through some regression models. The VUS can then
be defined as the concordance between the assigned disease category and the true disease
status. Therefore, the extension of the VUS to nominal competing outcomes is technically
straight-forward. This will be a topic of future research.
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